At the close of the recent quarter, Egalet Corp. (NASDAQ:EGLT)‘s balance sheet demonstrated total assets worth $135.33M and debt of 428,000%. Compared to the previous period, the debt increased/decreased by growing.
Egalet Corp.’s total liabilities closing the latest quarter was $152.49M.
Let’s look into the technical of the stock
The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.
The assets that the firm listed at the close of the recent quarter comprised cash balance of 26.99M%. Net operating cash from the previous quarter was $(20.61M), resulting in free cash flow of $(20.67M). Compared to the previous period, net change in case was $(17.37M).
The cash that Egalet Corp. generated in the previous quarter stemmed from sales of 5.43M%, which increased 0.51% in the same quarter, a year ago.
It cost Egalet Corp. some $1.83M to generate the sales of 5.43M% reported in the previous quarter as the cost of sales. After discounting the cost of sales in the income computations, Egalet Corp. emerged with gross income of $3.6M.
After considering other operating expenses, the firm closed with a net income figure. When that amount divided by the number of outstanding shares it closed up with EPS (earnings per share) of $(1.02). For perspective on how Egalet Corp. reached at the EPS figure, shareholders should know that the firm closed the last quarter with diluted due shares of 24.77M.
Wall Street analysts reported investors should anticipate from Egalet Corp. EPS of $-0.73 in the next quarter.
In addition to estimating the next quarter’s EPS, market analysts have weighed in on the stock of Egalet Corp. regarding whether shareholders should view it as a SELL, BUY or HOLD. Some 4 analysts have analyzed the stock so far, giving it an average recommendation of Buy.
Egalet Corporation (NASDAQ:EGLT) (“Egalet”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the prior approval supplement (PAS) of OXAYDO® (oxycodone HCl, USP) tablets C-II in 10 mg and 15 mg dosage strengths.